These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7369181)

  • 1. Antagonism of cefamandole by cefoxitin in routine disk susceptibility tests.
    Sanders CC; Sanders WE
    Am J Clin Pathol; 1980 Apr; 73(4):562-3. PubMed ID: 7369181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of BL-S786 with cephalothin, cefamandole and cefoxitin in vitro and in treatment of experimental infections in mice.
    Goering RV; Sanders CC; Sanders W
    J Antibiot (Tokyo); 1978 Apr; 31(4):363-72. PubMed ID: 306989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ["In vitro" activity of cefamandole, cefalotin, cefoxitin and cefuroxim against enterobacteria and Staphylococcus aureus isolated in hospital (author's transl)].
    Thabaut A; Durosoir JL; Saliou P
    Pathol Biol (Paris); 1979 Dec; 27(10):649-54. PubMed ID: 395496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases.
    Sanders CC; Sanders WE
    Antimicrob Agents Chemother; 1979 Jun; 15(6):792-7. PubMed ID: 314270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro comparison of cefoxitin, cefamandole, cephalexin, and cephalothin.
    Eickhoff TC; Ehret JM
    Antimicrob Agents Chemother; 1976 Jun; 9(6):994-9. PubMed ID: 938029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefuroxime, cefamandole, cefoxitin, and cephalothin in vitro susceptibility tests: reassessment of the "class representative" concept, confirmation of disk interpretive criteria, and proposed quality control guidelines.
    Barry AL; Jones RN; Thornsberry C
    Am J Clin Pathol; 1983 Aug; 80(2):182-9. PubMed ID: 6881092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of gentamicin-resistant Enterobacteriaceae to cefamandole and cefoxitin.
    Rosenthal SL; Freundlich LF; Quraishi MA
    Chemotherapy; 1979; 25(3):157-61. PubMed ID: 456076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of resistance determinants to cefamandole and cefoxitin in Enterobacter cloacae strains.
    Vuye A
    Microbios; 1983; 38(153-154):159-69. PubMed ID: 6606106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activities of cefamandole and cephalothin against 1,881 clinical isolates. A multi-center study.
    Barry AL; Schoenknect FD; Shadomy S; Sherris JC; Thornsberry C; Washington JA; Kammer RB
    Am J Clin Pathol; 1979 Nov; 72(5):858-60. PubMed ID: 506998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between cephalothin and newer parenterally absorbed cephalosporins in vitro: a justification for separate disks.
    Washington JA II
    J Infect Dis; 1978 May; 137 Suppl():S32-S37. PubMed ID: 349096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of cefaclor, cefazolin, cefamandole, and cephalothin disks to predict susceptibility of Enterobacteriaceae, Staphylococcus species, and Haemophilus influenzae.
    Barry AL; Jones RN; Thornsberry C
    Am J Clin Pathol; 1985 Nov; 84(5):643-8. PubMed ID: 3877452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of cefoxitin and cefamandole.
    Adams HG; Stilwell GA; Turck M
    Antimicrob Agents Chemother; 1976 Jun; 9(6):1019-24. PubMed ID: 820241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of carbenicillin and cefamandole by cefoxitin in treatment of experimental infections in mice.
    Goering RV; Sanders CC; Sanders WE
    Antimicrob Agents Chemother; 1982 Jun; 21(6):963-7. PubMed ID: 6921959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpretive criteria for cefamandole and cephalothin disk diffusion susceptibility tests.
    Barry AL; Schoenknecht FD; Shadomy S; Sherris JC; Thornsberry C; Washington JA; Kammer RB
    Antimicrob Agents Chemother; 1979 Jan; 15(1):140-1. PubMed ID: 106770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae.
    Gootz TD; Sanders CC; Goering RV
    J Infect Dis; 1982 Jul; 146(1):34-42. PubMed ID: 6979593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the cefonicid disk test criteria, including disk quality control guidelines.
    Barry AL; Jones RN; Thornsberry C
    J Clin Microbiol; 1983 Feb; 17(2):232-9. PubMed ID: 6601113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of a cefoxitin-inducible beta-lactamase in a case of breakthrough bacteremia.
    Beckwith DG; Jahre JA
    J Clin Microbiol; 1980 Oct; 12(4):517-20. PubMed ID: 6968320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaerobic bacteria: evaluation of disc susceptibility to four cephalosporins.
    Dubois J; Pechère JC
    Infection; 1978; 6(6):266-70. PubMed ID: 730395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of disk approximation and agar dilution induction tests for demonstration of in vitro antagonism of cefotaxime by cefoxitin in Enterobacter species.
    Chandler SW; Nolte FS
    Eur J Clin Microbiol; 1987 Aug; 6(4):476-8. PubMed ID: 3499317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefoxitin activity against multiply antibiotic-resistance Klebsiella pneumoniae in vitro.
    Jackson RT; Thomas FE; Alford RH
    Antimicrob Agents Chemother; 1977 Jan; 11(1):84-7. PubMed ID: 319753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.